Wall Street is shifting its view on two major names. Intel received a formal upgrade this week. The chip giant now has five Buy-equivalent ratings. That compares to four previously. The average analyst target sits at $84.43.
Pfizer also caught an upward target price revision. Analysts nudged the average target to $29.19. The pharma giant carries a $144 billion market cap. It remains under modest short pressure at just 2.8% of free float.
Fair Isaac Corporation drew attention too — but for the wrong reason. Its average analyst target slipped to $1,560. That is a small but notable trim for the scoring analytics firm. Short interest sits at 7.5% of free float, one of the higher readings in the group.
Consolidated Edison joined Intel with a fresh upgrade. The utility now counts seven Buy ratings against three Sells. Utilities gaining favour can signal defensive rotation.
Equifax and Ameren both saw consensus target prices trimmed. The moves are small but suggest caution at current valuations. lost a recommendation entirely, cutting active coverage to 34 from 35 analysts.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
